Patents by Inventor Wayne W. Hancock
Wayne W. Hancock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210340536Abstract: The present invention is directed to hybrid chimera antisense oligonucleotides including deoxyribonucleotide and 2?-deoxy-2?-fluoro-?-D-arabinonucleotide which binds to a Foxp3 mRNA, and to methods of use thereof. The methods include the use for reducing expression level of Foxp3 gene, increasing anti-tumor activity, and treating cancer in a subject.Type: ApplicationFiled: September 25, 2019Publication date: November 4, 2021Inventors: Veenu Aishwarya, Wayne W. Hancock
-
Patent number: 9717717Abstract: Methods and compounds for treating cancer by, for example, modulating immune system activity, are provided.Type: GrantFiled: July 28, 2016Date of Patent: August 1, 2017Assignees: Progenra, Inc., The Children's Hospital of PhiladelphiaInventors: Joseph Weinstock, Jian Wu, Suresh Kumar Kizhakkethil-George, Feng Wang, Matthew P. Kodrasov, Saket Agarwal, Wayne W. Hancock
-
Patent number: 9249087Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.Type: GrantFiled: January 31, 2012Date of Patent: February 2, 2016Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE CHILDREN'S HOSPITAL OF PHILADELPHIAInventors: Alan Kozikowski, Jay H. Kalin, Kyle V. Butler, Joel Bergman, Wayne W. Hancock
-
Publication number: 20140128408Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.Type: ApplicationFiled: January 31, 2012Publication date: May 8, 2014Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Alan Kozikowski, Jay H. Kalin, Kyle V. Butier, Joel Bergman, Wayne W. Hancock
-
Publication number: 20130323283Abstract: Methods for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease in a subject in need thereof comprise administering to the subject an effective amount of a pharmaceutical composition comprising an inhibitor of a histone/protein acetyltransferase (HAT). Methods for identifying an agent useful for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease comprise (a) contacting a candidate agent with a test sample comprising Foxp3+ T regulatory cells (Tregs), and (b) comparing a function of the Foxp3+ Tregs in the test sample with that in a control sample, wherein inhibition of the function of the Foxp3+ Tregs in the test sample when compared with the control sample indicates that the candidate agent is an agent useful for treating or preventing a Foxp3+ Treg related disease.Type: ApplicationFiled: December 1, 2011Publication date: December 5, 2013Applicants: THE CHILDREN'S HOSPITAL OF PHILADELPHIA, THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Wayne W. Hancock, Steven M. Albelda, Philip A. Cole
-
Patent number: 8497285Abstract: This invention is in the fields of immunology and autoimmunity. More particularly it concerns methods of treating patients with compounds which are useful agents for inhibiting the functions of TIP60 in the treatment of an individual suffering, for example, from ulcerative colitis and other irritable bowel diseases.Type: GrantFiled: December 2, 2011Date of Patent: July 30, 2013Assignees: The Trustees Of The University Of Pennsylvania, The Children's Hospital of PhiladelphiaInventors: Mark I. Greene, Wayne W. Hancock, Makoto Katsumata, Yan Xiao
-
Publication number: 20120202848Abstract: This invention is in the fields of immunology and autoimmunity. More particularly it concerns methods of treating patients with compounds which are useful agents for inhibiting the functions of TIP60 in the treatment of an individual suffering, for example, from ulcerative colitis and other irritable bowel diseases.Type: ApplicationFiled: December 2, 2011Publication date: August 9, 2012Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: MARK I. GREENE, WAYNE W. HANCOCK, MAKOTO KATSUMATO, YAN XIAO
-
Publication number: 20100310635Abstract: Methods, compositions and kits effective for modulating and immunomonitoring of Treg activity are provided. Therapeutic methods involving formation and uses of cleaved Foxp3 are disclosed, as well as screening assays for identifying agents effective for modulating Treg activity.Type: ApplicationFiled: April 25, 2008Publication date: December 9, 2010Inventors: Engin Ozkaynak, Wayne W. Hancock
-
Patent number: 7348336Abstract: The subject matter of the present invention is directed to novel substituted ?-carbolines, and specifically compounds of the formula I, which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I?B kinase is involved.Type: GrantFiled: March 28, 2006Date of Patent: March 25, 2008Assignee: Sanofi-Aventis Deutschland GmbHInventors: Olaf Ritzeler, Alfredo Castro, Louis Grenier, Francois Soucy, Wayne W. Hancock, Hormoz Mazdiyasni, Vito Palombella, Julian Adams
-
Patent number: 7026331Abstract: The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I, which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I?B kinase is involved.Type: GrantFiled: July 28, 2003Date of Patent: April 11, 2006Assignee: Sanofi-Aventis Deutschland GmbHInventors: Olaf Ritzeler, Alfredo Castro, Louis Grenier, Francois Soucy, Wayne W. Hancock, Hormoz Mazdiyasni, Vito Palombella, Julian Adams
-
Publication number: 20040110759Abstract: The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I, 1Type: ApplicationFiled: July 28, 2003Publication date: June 10, 2004Applicant: AVENTIS PHARMA DEUTSCHLAND GMBHInventors: Olaf Ritzeler, Alfredo Castro, Louis Grenier, Francois Soucy, Wayne W. Hancock, Hormoz Mazdiyasni, Vito Palombella, Julian Adams
-
Patent number: 6627637Abstract: The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I, which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I&kgr;B kinase is involved.Type: GrantFiled: March 15, 2001Date of Patent: September 30, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Olaf Ritzeler, Alfredo Castro, Louis Grenier, Francois Soucy, Wayne W. Hancock, Hormoz Mazdiyashi, Vito Palombella, Julian Adams
-
Publication number: 20020160947Abstract: The invention relates to allograft transplantation. More particularly, the invention relates to prolonging the survival of transplanted allografts. The invention provides a new method for improving allograft survival in a mammal. The method according to the invention provides a synergistic effect between lactacystin or lactacystin analogs and immunosuppressive drugs to prolong the survival of transplanted allografts in a mammal.Type: ApplicationFiled: April 2, 2002Publication date: October 31, 2002Applicant: Millennium Pharmaceuticals, Inc.Inventors: Peter J. Elliott, Wayne W. Hancock
-
Publication number: 20020099068Abstract: The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I, 1Type: ApplicationFiled: March 15, 2001Publication date: July 25, 2002Inventors: Olaf Ritzeler, Alfredo Castro, Louis Grenier, Francois Soucy, Wayne W. Hancock, Hormoz Mazdiyasni, Vito Palombella, Julian Adams
-
Publication number: 20020042370Abstract: A method for inhibiting the rejection of transplanted grafts is disclosed. The method comprising administering an effective amount of an antagonist of CCR2 function to a graft recipient. The disclosed methods can also comprise the co-administration of one or more additional therapeutic agents, for example, immunosuppressive agents.Type: ApplicationFiled: April 13, 2001Publication date: April 11, 2002Applicant: Millennium Pharmaceuticals, Inc.Inventor: Wayne W. Hancock
-
Publication number: 20020018776Abstract: A method for inhibiting the rejection of transplanted grafts is disclosed. The method comprising administering an effective amount of an antagonist of CXCR3 function to a graft recipient. The disclosed methods can also comprise the co-administration of one or more additional therapeutic agents, for example, immunosuppressive agents.Type: ApplicationFiled: April 13, 2001Publication date: February 14, 2002Applicant: Millennium Pharmaceuticals, Inc.Inventor: Wayne W. Hancock
-
Publication number: 20020019345Abstract: A method for inhibiting the rejection of transplanted grafts is disclosed. The method comprising administering an effective amount of an antagonist of CCR5 function to a graft recipient. The disclosed methods can also comprise the co-administration of one or more additional therapeutic agents, for example, immunosuppressive agents.Type: ApplicationFiled: April 13, 2001Publication date: February 14, 2002Applicant: Millennium Pharmaceuticals, Inc.Inventor: Wayne W. Hancock
-
Patent number: RE47009Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.Type: GrantFiled: June 14, 2016Date of Patent: August 28, 2018Assignees: THE CHILDREN'S HOSPITAL OF PHILADELPHIA, THE TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Alan Kozikowski, Jay Hans Kalin, Kyle Vincent Butler, Joel Bergman, Wayne W. Hancock